SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

Annovis Bio Submits An International Patent Application Under Patent Cooperation Treaty To Cover Treatment Of Neurological Injuries Caused By Infections

BERWYN, Pa., June 9, 2022 /PRNewswire/ -- Annovis Bio (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today

Benzinga · 06/09/2022 08:36

BERWYN, Pa., June 9, 2022 /PRNewswire/ -- Annovis Bio (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that the company submitted an international patent application under the Patent Cooperation Treaty for its drug platform buntanetap. The patent claims a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans.